ATE210995T1 - Interleukin-11 präparat - Google Patents

Interleukin-11 präparat

Info

Publication number
ATE210995T1
ATE210995T1 AT95911976T AT95911976T ATE210995T1 AT E210995 T1 ATE210995 T1 AT E210995T1 AT 95911976 T AT95911976 T AT 95911976T AT 95911976 T AT95911976 T AT 95911976T AT E210995 T1 ATE210995 T1 AT E210995T1
Authority
AT
Austria
Prior art keywords
interleukin
preparation
glycine
histidine
lyophilized
Prior art date
Application number
AT95911976T
Other languages
English (en)
Inventor
Nicholas W Warne
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst filed Critical Genetics Inst
Application granted granted Critical
Publication of ATE210995T1 publication Critical patent/ATE210995T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95911976T 1994-04-21 1995-02-28 Interleukin-11 präparat ATE210995T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/230,982 US6270757B1 (en) 1994-04-21 1994-04-21 Formulations for IL-11
PCT/US1995/002452 WO1995028951A1 (en) 1994-04-21 1995-02-28 Formulations for il-11

Publications (1)

Publication Number Publication Date
ATE210995T1 true ATE210995T1 (de) 2002-01-15

Family

ID=22867340

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95911976T ATE210995T1 (de) 1994-04-21 1995-02-28 Interleukin-11 präparat

Country Status (8)

Country Link
US (1) US6270757B1 (de)
EP (1) EP0758901B1 (de)
JP (2) JP4118326B2 (de)
AT (1) ATE210995T1 (de)
AU (1) AU684620B2 (de)
CA (1) CA2182199C (de)
DE (1) DE69524742T2 (de)
WO (1) WO1995028951A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7230014B1 (en) 1997-10-14 2007-06-12 Eisai Co., Ltd. Pharmaceutical formulation comprising glycine as a stabilizer
DK1039905T3 (da) * 1997-10-14 2006-11-06 Eisai Co Ltd Farmaceutisk formulering omfattende glycin som en stabilisator
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
BR0012429A (pt) * 1999-07-15 2002-09-17 Genetics Inst Fórmulações para il-11
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
AU2002362088A1 (en) * 2001-12-06 2003-06-23 Catholic University Method and composition for inducing weight loss
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
NZ567324A (en) * 2003-02-01 2009-08-28 Wyeth Corp Active immunization to generate antibodies to soluble A-beta
PE20050627A1 (es) * 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
SV2008002394A (es) * 2005-01-28 2008-02-08 Wyeth Corp Formulaciones liquidas estabilizadas de polipeptido ref. ahn- 072sv
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US7718622B2 (en) * 2005-03-04 2010-05-18 Dynavax Technologies Corporation Compositions comprising structurally stable conjugate molecules
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US20080069796A1 (en) * 2006-07-31 2008-03-20 Kim Jong-Mook Low Dose Treatment with an Interleukin-11 Analog
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US7951368B2 (en) * 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
JP5889529B2 (ja) 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3262575D1 (en) * 1981-12-23 1985-04-18 Schering Corp Stabilised interferon formulations and their preparation
US4774091A (en) * 1983-10-14 1988-09-27 Sumitomo Pharmaceuticals Company, Ltd. Long-term sustained-release preparation
DE3583880D1 (de) 1984-04-09 1991-10-02 Takeda Chemical Industries Ltd Stabile interleukin-2-zusammensetzung.
JPS60243028A (ja) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd インタ−フエロンの可溶化方法
ES2058351T3 (es) * 1988-01-29 1994-11-01 Sumitomo Pharma Un procedimiento para producir una formulacion de liberacion sostenida que es adecuada para el uso humano y veterinario.
US5215743A (en) * 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5215895A (en) * 1989-11-22 1993-06-01 Genetics Institute, Inc. Dna encoding a mammalian cytokine, interleukin-11
US5371193A (en) * 1990-05-21 1994-12-06 Genetics Institute, Inc. - Legal Affairs Mammalian cytokine, IL-11
US5292646A (en) 1991-02-06 1994-03-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US5270181A (en) 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
EP0578823B1 (de) 1991-04-08 2002-01-23 Sumitomo Pharmaceuticals Company, Limited Poröse feste zubereitung, die eine physiologische aktive proteinverbindung enthält
US5460810A (en) 1992-09-02 1995-10-24 Genetics Institute, Inc. Method for maintaining gut epithelial cells by treatment with a cytokine such as interleukin 11
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations

Also Published As

Publication number Publication date
DE69524742T2 (de) 2002-08-14
EP0758901B1 (de) 2001-12-19
JP4118326B2 (ja) 2008-07-16
JPH09512529A (ja) 1997-12-16
AU1934495A (en) 1995-11-16
EP0758901A1 (de) 1997-02-26
AU684620B2 (en) 1997-12-18
WO1995028951A1 (en) 1995-11-02
CA2182199A1 (en) 1995-11-02
DE69524742D1 (de) 2002-01-31
US6270757B1 (en) 2001-08-07
JP2007217439A (ja) 2007-08-30
CA2182199C (en) 2008-06-17

Similar Documents

Publication Publication Date Title
ATE210995T1 (de) Interleukin-11 präparat
ATE270557T1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
ATE244015T1 (de) Formulierungen fuer faktor ix
DK1093819T3 (da) Forbindelse og præparat til tilförsel af aktive midler
BR0012429A (pt) Fórmulações para il-11
FI964681A (fi) Ihmisperäiset Lactobacillus-kannat, niitä sisältävät valmisteet ja niiden käytöt
EP1100522A4 (de) Verabreichung aktiver wirkstoffe über die lunge
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
FI973828A0 (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
IL113812A0 (en) Copolymer-1, pharmaceutical compositions containing it and its use
FI955042A (fi) Syklosporiinia sisältävä jauhemainen koostumus
FI953442A0 (fi) Gonadotropiinia sisältäviä pakastekuivattuja pallosia
BG104315A (en) Prostaglandine agonists and their application for the treatment of osteal diseases
BG103657A (en) New modifications of 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonylaminebenzene and methods for their prepration
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
KR100547921B1 (ko) 설폰아미드-치환된크로만,이의제조방법및이를포함하는약제학적조성물
WO1998019697A3 (en) Novel pharmaceutical compositions
MY112148A (en) Suspension concentrate compositions of arylpyrrole insecticidal and acarricidal agents
IT1270618B (it) Proteine ad attivita' antitumorale
TR199901209T2 (xx) B�cek �ld�r�c� ve mitisidal kompozisyonlar
AU6849198A (en) Neurotrypsin
IL128500A (en) SUBSTITUTED 1,2,3,4-TETRAHYDRO-2-DIBENZOFURANAMINES AND 2-AMINOCYCLOHEPTA[b] BENZOFURANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DK0588177T3 (da) Interferon-alpha/beta-bindende protein, fremstilling heraf samt farmaceutiske præparater indeholdende proteinet
BR9609114A (pt) Composição inseticida de terra diatomácea
NO963113D0 (no) Farmasöytiske preparater omfattende hirudin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties